

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/11038 A2

- (51) International Patent Classification⁷: C12N 15/11 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/EP00/07731
- (22) International Filing Date: 9 August 2000 (09.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
99870171.8 9 August 1999 (09.08.1999) EP
- (71) Applicant (*for all designated States except US*): UNIVERSITE CATHOLIQUE DE LOUVAIN [BE/BE]; Place de l'Université 1, B-1348 Louvain-la-Neuve (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): BALLIGAND, Jean-Luc [BE/BE]; Place de la Chapelle 1, B-1950 Kraainem (BE). FERON, Olivier [BE/BE]; Van Severlaan 3, B-1970 Wezembeek-Oppem (BE).
- (74) Agent: BRANTS, Johan, Philippe, Emile; De Clercq, Brants & Partners, E. Gevaertdreef 10 a, B-9830 Sint-Martens-Latem (BE).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A2

WO 01/11038 A2

(57) Abstract: The present invention is related to a compound or a pharmaceutical composition thereof for the use of a medicament in the modulation of angiogenesis through the tackling of the intracellular free cholesterol-caveolin1-eNOS-NO pathway. The present invention also provides a method of study, testing, screening and manufacturing of new compounds or compositions which influence the angiogenesis pathway and to a method for identifying a compound or composition having possible therapeutic angiogenic properties for the treatment of diseases associated with vascular disease, including cerebral diseases, tumor growth, and peripheral vascular diseases.

USE OF COMPOUND OR PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND/OR THE TREATMENT OF ISCHEMIC HEART AND PERIPHERAL VASCULAR DISEASES, TUMOUR DEVELOPMENT AND FOR WOUND HEALING

5 Field of the invention

The present invention is related to a compound or a pharmaceutical composition thereof for use as a medicament for the modulation of angiogenesis for the prevention and/or the treatment of various diseases and pathologies of mammals, including of human, such as ischemic heart and peripheral vascular including cerebral diseases and tumour development and for wound healing.

The present invention is also related to a method of study, testing and/or screening of new compounds or compositions which may be used for the treatment or the prevention of said various diseases and pathologies.

15

Technological background of the invention

A therapeutic angiogenesis favour the development of collateral vessels to revascularise ischemic territories. Administration of angiogenic cytokines was recently proposed as an alternative to surgery or percutaneous transluminal coronary angioplasty (PTCA) for patients suffering from ischemic cardiomyopathy. This approach is hampered by two major limitations:

- the presence of a diseased and dysfunctional endothelium in ischemic tissue alters its sensitivity to angiogenic cytokines and renders their use difficult to standardise; many contradictory reports on angiogenic properties of these cytokines stemmed from inconsistencies of their effects in vitro versus in vivo, or according to the dose used;

- the need to maintain a high local concentration of cytokines is a special challenge given numerous side effects, i.e. hypotension, consecutive to the administration of high bolus doses of angiogenic factors; alternatively, the repetitive administration of recombinant proteins is too costly

The specific properties of angiogenic cytokines may induce the necrosis of tissues that are no longer irrigated by specific affected blood vessels. It is known that coronary vessels

supplying oxygen and nutrients are essential for the irrigation of the cardiac muscle. A coronary insufficiency (for instance, induced by atherosclerosis) can be corrected by angioplasty with dilatation of the vessel obstructed by a cholesterol deposit or by surgery by bridging the non-affected portions of the vessel. However, said techniques present 5 several drawbacks or limitations like their costs, possible re-occlusion of the dilated vessel or side effects of said surgery.

NO is produced in endothelial cells by a Ca^{2+} /calmodulin-dependent enzyme, the endothelial isoform nitric oxide synthase (eNOS). It has been recently shown that eNOS is located in plasmalemmal invaginations termed caveolae, and specifically interacts with 10 cell-specific isoforms of caveolin, the structural protein of caveolae (Feron et al., 1996). Further experiments have revealed that this association leads to the inhibition of the enzyme activity and that a stable protein-protein interaction takes place between both proteins (Michel et al., 1997a; Feron et al., 1998a), i.e. eNOS and caveolin-1 in endothelial cells or eNOS and caveolin-3 in cardiac myocytes. Consensus sequences were identified 15 within both proteins: the scaffolding domain of caveolin, a juxtamembrane region of 20 amino acids in the C-terminal moiety of caveolin (Michel et al., 1997b), and a putative caveolin binding motif, a peptide sequence rich in aromatic residues localised in the oxygenase domain of eNOS (Feron et al., 1998a; Garcia Cardena et al., 1997). In order for eNOS to be fully activated, caveolin must dissociate from the enzyme. The ubiquitous 20 Ca^{2+} regulatory protein calmodulin (CaM) disrupts the heteromeric complex formed between eNOS and caveolin in a Ca^{2+} -dependent fashion (Michel et al., 1997a; Feron et al., 1998b): caveolin serves as a competitive inhibitor of CaM-dependent eNOS activation (Michel et al., 1997b; Michel and Feron, 1997).

As a corollary the activity of eNOS in cells is influenced by changes in the equilibrium 25 between these two protein-protein interactions upon stoichiometric changes in the abundance of either of these partners. It has been shown that in cardiac myocytes, the transfection of a caveolin-3 construct or the loading of a synthetic peptide corresponding to caveolin scaffolding domain leads to the decrease in NO production at the basal level as well as following agonist stimulation (Feron et al., 1998c). Furthermore,

mation with eNOS (Feron et al., 1999). Functional consequences following changes in the abundance of caveolin-3 or the use of caveolin-like peptides have been illustrated in models of cultured myocytes in vitro, with alterations of the sensitivity of their beating rate to parasympathetic stimulation (Feron et al., 1998c)

5 Due to its complex biochemistry in biological milieu, NO release from exogenous donor drugs does not recapitulate all the effects of NO as produced endogenously by nitric oxide synthases. Therefore, it is necessary to develop specific biochemical processes that are involved in the promotion or the inhibition of nitric oxide release, which finds applications in the prevention and/or the treatment of various diseases and pathologies like ischemic heart and peripheral vascular including cerebral diseases, wound healing and/or tumour development.

10 15 However, today, there is no published demonstration of the impact of the alterations in the abundance of caveolin-1 on the physiological behaviour of endothelial cells (downstream from their production of NO).

15 20 25 3-Hydroxy-3-methylglutaryl coenzyme A (HMGCo A) reductase inhibitors (or statins) were shown to substantially reduce cardiovascular morbidity and mortality in clinical primary and secondary prevention trials (Maron et al. 2000). Although it was reasonable to attribute most (if not all) of these therapeutic benefits to the reduction in atherogenesis secondary to their effect on serum lipid profile, recent studies suggested otherwise. Indeed, statins reduced clinical end points before any measurable regression in atherosclerotic plaques (MAAS. The Multicentre Anti-Atheroma Study, 1994), diminished cardiovascular mortality even in patients with average cholesterol levels (Sacks et al. 1996; Byington et al. 1995) and restored normal endothelial function independently of their effects on serum cholesterol levels (O'Driscoll et al., 1997). These clinical benefits apparently unrelated to the central (hepatic) effect of statins to reduce LDL cholesterol have been explained by several mechanisms (the so-called pleiotropic effects of statins), including prevention of intimal thickening through induction of vascular smooth muscle cell (VSMC) apoptosis (Guizarro et al, 1998) and inhibition of VSMC migration (Hidaka et al. 1992) and proliferation (Corcini et al. 1999, 2000).

20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999

Laufs et al. 1998) and/or activity (Kaesemeyer et al. 1999). Although in most of these studies, the effect of statins have been ascribed to the inhibition of the mevalonate-dependent geranylgeranylation of Rho GTPase proteins, the causal relationship between this phenomenon and the protective effect of statins on vessel function remains elusive.

Following patents/applications can be found: The document JP-10087698 describes the use of human heart caveolin peptide or its corresponding DNA for preventing and treating diabetes, obesity, cancer, arteriosclerosis and muscular dystrophy. This document relates to the use of the muscle-specific isoform of caveolin (or caveolin-3) but does not refer to the use of endothelial caveolin isoform (caveolin-1). Methods for diagnosis, evaluation and treatment of hormone-resistant cancers using caveolin antisense sequences to target tumour cells are covered in WO99/22773; certain cancers may be treated by therapies which suppress expression of the caveolin-1 gene. WO99/46592 targets proliferating cells by increasing the caveolin-1 to decrease mitosis.

It is also known to obtain a modulation of the NO production by the use of L-arginine-derived drugs or various drugs mixtures (as described in the documents WO98/48826, WO95/11014, US-5,767,160 and US-5,543,430) or with strategies based upon the exploitation of eNOS sequence (as described in the documents WO98/02555, JP-10136989, WO96/01902, WO93/18156), to target atherogenesis and restenosis (as described in the document US-5,428,070).

The production of statins and semi synthetic statins are described in WO9837220, AU6726398, WO9910499 and EP0971913. Statins are described to be used for the treatment of viral diseases (FR2646353, ZA9106638), eye complains (CA2018209, EP0402203, JP3034934, US5134124), angina pectoris, atherosclerosis, combined hypertension and hyperlipidia (WO9911263), hypertension (US4749687, EP0155809, US4755592, EP0165151) vascular diseases (WO9930704, WO9930706) and cardiac risk (WO9911263, Pfizer, WO9947123).

The present invention aims to provide new compounds, compositions and/or methods which may improve the prevention and/or the treatment of various angiogenesis related diseases or pathologies of mammals, including the human, which do not present the drawbacks of the state of the art. Another aim of the present invention is to 5 provide a method of study, testing, screening and manufacturing of new compounds or compositions which influences the angiogenesis.

The present invention is related to a compound for use as a medicament in the modulation of angiogenesis through the tackling of the intracellular free cholesterol-caveolin1-eNOS-NO pathway. With "tackling" it is meant that activities of the molecules 10 that form part of this pathway can be promoted or inhibited and/or concentrations of these can be increased or decreased resulting in a modulated angiogenesis. Increase in angiogenesis would be beneficial in a variety of ischemic cardiovascular diseases. Inventors showed that molecules such as statins decrease caveolin-1 abundance ensuring more eNOS activity; more NO resulting in an increased angiogenesis. Decrease in angiogenesis would be beneficial in angiogenesis-dependent tumour growth and metastatic 15 diseases through drugs that increase intracellular free cholesterol, and thereby increase caveolin-1 abundance.

The inventors showed for the first time that angiogenesis can be modulated directly through the modulation cholesterol metabolism and its effect on NO production.

Several different angiogenic activators have been described sofar. These include, 20 but are not limited to FGF, VEGF and HGF. These growthfactors bind and activate specific receptor tyrosine kinases within the endothelial cells that are coupled to a variety of signal transduction pathways, most probably the Ras-p42/44 MAP kinase pathway. Liu et al. (1999) showed that both angiogenesis activators and inhibitors have also an effect 25 on the expression of caveolin-1 and suggest that down-regulation of caveolin-1 by angiogenic growth factors may be important for endothelial cell proliferation and subsequent angiogenesis. Nevertheless, a direct link between caveolin-modulated NO increase and angiogenesis has never been made. Caveolin is a multifunctional protein known to influence many pathways or signal transduction cascades according to the cell type or

genes, adenylylate cyclase and G-protein-coupled receptors (Smart et al. (1999)). Consequently, it is not obvious to associate the effect of cytokines with caveolin-regulated NO

production. The inventors proved for the first time that NO has a direct effect on angiogenesis through changes in the abundance of the scaffolding protein caveolin.

Statins inhibit the HMG-CoA reductase and have a beneficial effect in patients with coronary heart disease through the reduction in atherogenesis and the correction of associated endothelial dysfunction (Maron et al., 2000). Although statins have been shown to increase NO availability (Laufs et al., 1998; Hernandez-Perera et al., 1998; Kaesemeyer et al., 1999; Wagner et al., 2000), to improve vasodilatation (O'Driscoll et al., 1997) and to modulate the proliferation and the programmed cell death of vascular smooth cells (Guillarro et al., 1998; Corsini et al., 1998), it has never been linked to its modulating effect on angiogenesis. The inventors proved that modifying the intracellular cholesterol content (using statins) influence angiogenesis directly via this newly described intracellular free cholesterol-caveolin1-eNOS-NO pathway.

With the "intracellular free cholesterol-caveolin1-eNOS-NO pathway" is meant that there exists a direct link between all members of this pathway, wherein members are caveolin, eNOS, NO, HMGCoA reductase, HMGCoA synthase and the other enzymes of the mevalonate pathway (Goldstein and Brown, 1990), calmodulin, Hsp90, LDL and HDL receptors,. The present invention is directed to all the members of this pathway as pharmaceutical target to influence angiogenesis.

The experimental data shown below directly implicate the inhibition by atorvastatin of cholesterol synthesis in endothelial cells as the mechanism promoting NO release (experiment 1). In addition, inventors showed for the first time that statins have a promoting effect on tube formation by this effect on caveolin abundance (experiment 2 and 3).

By reducing the cholesterol content in endothelial cells, the inventors have discovered unexpectedly that in endothelial cells, the caveolin-1 down-regulation is correlated with an increase in NO release, probably by a stoichiometric regulation of eNOS activity by a cellular pool of caveolin. In addition, exposure to high cholesterol concentrations decreases NO production through an upregulation of the abundance of endogenous caveolin-1

25
variations in the total amount of many proteins involved in sterol flux and metabolism, e.g.
LDL receptor, HMG CoA synthase and reductase (Fielding and Fielding, 1997). In addi-

tion, the balance between external and internal cholesterol is maintained through the efflux of free cholesterol to high density lipoproteins (HDL), a process involving discrete plasmalemmal microdomains termed caveolae (Fielding and Fielding, 1997; Bist et al. 1997). Recently, the inventors demonstrated in endothelial cells that the level of expression of caveolin-1, the main structural component of caveolae, is directly related to the amount of extracellular LDL-cholesterol and subsequent cholesterol uptake by these 5 cells (Feron et al., 1999). Importantly, the inventors documented that the increase in caveolin abundance induced by high LDL-cholesterol promotes its inhibitory interaction with eNOS, resulting in a decrease in NO production (Feron et al., 1999). This mechanism of cholesterol-induced impairment of NO production may participate in the proatherogenic effects of hypercholesterolemia and more generally in the pathogenesis of 10 endothelial dysfunction, i.e. the deterioration of the vasodilator function of the endothelium and the dysregulation of endothelial-blood cell interactions (which may lead to localized inflammation and thrombosis). Inventors hypothesized that by reducing circulating 15 LDL-cholesterol, or directly inhibiting cholesterol synthesis in endothelial cells, statins could reverse endothelial dysfunction by decreasing caveolin expression and promoting NO release through the destabilization of the inhibitory caveolin/eNOS complex.

To test this hypothesis, the inventors incubated endothelial cells with increasing 20 doses of the HMGCoA reductase inhibitor atorvastatin and studied the effects on caveolin protein expression levels, caveolin/eNOS interaction and eNOS activity. These experiments were performed in absence and in presence of human LDL-cholesterol fractions in order to verify the modulation of NOS activity by the statin in conditions of significant cholesterol influx from an extracellular source. Results show that very low doses 25 of atorvastatin (0.01-0.1 µmol/L) significantly reduced caveolin abundance and restored basal and agonist-stimulated NOS activity by altering the stoichiometry of eNOS complexation with caveolin and Hsp90, thereby underlying a novel regulation of eNOS activity by atorvastatin at the post-translational level.

Tackling of the proposed "intracellular free cholesterol/caveolin-1/eNOS/NO path-

way" (see above) - resulting in the modulation of the cholesterol metabolism (HMGCoA reductase, HMGCoA synthase and the other enzymes of the mevalonate

pathway, LDL and HDL receptors) or via targets which are located downstream within this pathway such as caveolin-1, calmodulin, Hsp90, eNOS and NO.

According to a preferred embodiment of the invention the compound for use as a medicament for the modulation of angiogenesis results in the modulation of the intracellular free cholesterol concentration (cholesterol metabolism and/or cholesterol flux).
5 The inventors showed that high cholesterol concentrations decreases NO production through an upregulation of the abundance of endogenous caveolin-1 and the subsequent inhibitory heterocomplex formation with eNOS (Feron et al., 1999). In addition, the inventors showed that this could be reversed by the addition of a statin (experiment
10 1) and that modifying the intracellular cholesterol content influence angiogenesis directly (experiment 2 and 3). Consequently, angiogenesis can be stimulated through the downregulation of the caveolin-1.

The present invention is related to a compound for use as a medicament for the modulation of angiogenesis which is chosen from the group comprising HMGCoA reductase inhibitors or a pharmacologically acceptable derivative thereof. The inventors showed that said inhibitors influence cholesterol metabolism resulting in the decrease of
15 the caveolin-1 abundance thereby increasing endothelium proliferation and resulting in the stimulation of angiogenesis.

According to present invention atorvastatin influences NO production and angiogenesis. Therefore a preferred embodiment of present invention describes the use of atorvastatin for use as a medicament for the modulation of angiogenesis. Compounds with similar structures such as mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin and cerivastatin will result in the same effect as described for atorvastatin.
20

Increase in caveolin-1 abundance can be achieved with drugs referred to as "ACAT
25 inhibitors" ("inhibitors of Acyl-co-A Cholesterol Acyl Transferase"). Therefore said compounds can be used as a medicament for the modulation of angiogenesis. ACAT inhibitors decrease the storage of cholesterol as cholesterol-esters, thereby increasing intracellular cholesterol, that in turn, will increase caveolin-1 expression. ACAT inhibitors include the following: avasimibe, NTF122, compound 58 035, TS-962 and the bacterial

Preferably, said ACAT inhibitor is used as a medicament for the modulation of angiogenesis is chosen from the group comprising avasimibe, NTE122, compound 58-035, TS-962 and the bacterial product epicochlioquinone A.

The present invention also relates to a compound for use as a medicament for the modulation of angiogenesis and able to increase the export of cholesterol out of peripheral cells through the increased abundance of HDL particles. The increased export of cholesterol decreases the intracellular cholesterol content resulting in the decrease of the caveolin-1 expression.

Preferably, a compound for use as a medicament for the modulation of angiogenesis which is chosen from a group comprising fenofibrate, bezafibrate and ciprofibrate. It is obvious for a person skilled in the art that a pharmacologically acceptable derivative thereof will also result in the same effect.

The present invention also relates to a compound for use as a medicament for the modulation of angiogenesis which decreases the production of cholesterol-rich VLDL particles by the liver.

Preferably, a compound for use as a medicament for the modulation of angiogenesis is chosen from a group comprising nicotinic acid. It is obvious for a person skilled in the art that a pharmacologically acceptable derivative thereof will also result in the same effect.

The present invention also relates to a compound or composition for use as a medicament for the modulation of angiogenesis influencing abundance and/or activity of caveolin, eNOS, calmodulin or Hsp90. Abundance can be modulated by the addition of active recombinant molecules (peptide or corresponding coding oligonucleotides) or influencing their endogenous production.

A preferred embodiment of the invention relates to a compound or composition for use as a medicament for the modulation of angiogenesis comprising recombinant caveolin-1, recombinant eNOS, recombinant calmodulin, recombinant Hsp90 or a pharmacologically acceptable derivative thereof. In this approach the concentration of active molecules is increased. With a "pharmacologically acceptable derivative" is meant a

100% identical molecule or a molecule which can be produced externally and added to the cell or produced intracellularly by adding expression vectors carrying respective coding regions

and expression signals allowing the production of active polypeptides. Therefore, the present invention also relates to a compound for use as a medicament for the modulation of angiogenesis which is a nucleic acid encoding the partial or total amino acid sequence of caveolin-1 or an analogue which can increase the caveolin-1 concentration in the cell thereby increasing the scavenging of the endogenous eNOS and reducing angiogenesis. Inhibition of angiogenesis is especially desired in the treatment of solid tumours and their metastases thereby preventing nutrient and oxygen supply of the cancer cells. Present invention shows that angiogenesis is directly linked to the increased production of NO and consequently linked to the decrease of endogenous caveolin-1. Inventors therefore suggest the use of caveolin-1 sense sequences for the treatment of cancer; this is the opposite of WO99/22773 where the use of caveolin-1 antisense molecules is suggested to target hormone-resistant cancers. Alternatively, the present invention describes a compound for use as a medicament for the modulation of angiogenesis which is a nucleic acid encoding the partial or total amino acid sequence of eNOS or an analogue thereof which can increase the eNOS concentration and/or activity in the cell thereby increasing the production of NO. Which expression signals are needed for the efficient expression of respective proteins is known by a person skilled in the art. Expression can be constitutive or controlled in a specific manner.

The present invention also relates to a compound for use as a medicament for the modulation of angiogenesis which is able to change the concentration of endogenous caveolin-1, eNOS, calmodulin or Hsp90 resulting in the modulation of angiogenesis. Said change can result from the modulation of the expression of respective molecules thereby interfering with promotor/silencer/activator molecules influencing the messenger RNA population or by influencing the translation or stability of respective messenger RNA.

According to a preferred embodiment of present invention the compound for use as a medicament for the modulation of angiogenesis may be an antisense nucleic acid sequence able to hybridise with a corresponding nucleotide sequence encoding the caveolin-1 thereby inhibiting the expression of the caveolin-1 protein in the cell.

Using the partial or total amino acid sequence of caveolin-1, preferably comprised into a recombinant expression vector, under the control of a regulatory sequence that allows

its expression (preferably its high expression) in a transfected cell. Preferably, SEQ ID NO 5 is used as antisense sequence. The vectors that can be used for the integration of said genetic sequence are plasmids or viral vectors (such as adenoviruses), which are able to be used for the transfection of endothelial cells *in vitro*, *in vivo* or *ex-vivo*.

- 5 A preferred embodiment of the invention relates to a compound for use as a medicament for the modulation of angiogenesis consisting of an antagonist or agonist of caveolin-1, eNOS, calmodulin or Hsp90. Said antagonists can antagonise the function of the molecule per se or act as a competitive inhibitor by inhibiting the binding of binding partners. A competitive inhibitor can also be defined as being a scavenging molecule or
10 a molecule able to trap one of the molecules defined to take part in the intracellular free cholesterol-caveolin1-eNOS-NO pathway.

Another preferred embodiment of the invention relates to a compound for use as a medicament for the modulation of angiogenesis which is able to trap the endogenous caveolin-1 preventing its binding to the endothelial isoform nitric oxide synthase (eNOS).
15 Possible compounds according to the invention are short peptidic sequences corresponding to the active sites upon eNOS to caveolin-1 such as described below. Said peptides can be made synthetically or produced in a cellular system. Systems that can be used to produce such proteins are known by the person skilled in the art.

According to present invention the compound for use as a medicament for the modulation of angiogenesis may also be a nucleic acid preferably comprised into a vector encoding the partial or total amino acid sequence of eNOS as described above or the eNOS sequence mutated or deleted in the active (caveolin) binding site or an analogue thereof which can increase the concentration of unbound (activated) eNOS. Possible compounds according to the invention are short peptidic sequences corresponding to the active sites (having preferably at least the common pattern SEQ ID NO 4, more preferably the pattern SEQ ID NO 6 to 86) upon eNOS to the caveolin-1 scaffolding domains A and B (described in the following sequences SEQ ID NO 2 and SEQ ID NO 3).

The present invention also relates to a compound for use as a medicament for the modulation of angiogenesis which is able to trap the endogenous eNOS mimicking the

compounds mentioned in the invention are short peptidic sequences corresponding to the active sites upon caveolin-1 to the eNOS such as described below.

According to present invention the compound for use as a medicament for the modulation of angiogenesis may be a nucleotide sequence encoding the partial or total amino acid sequence of caveolin-1. Alternatively, an analogue to these can be used. Increase in caveolin-1 concentration in the cell results in the increase scavenging of the endogenous eNOS. Scavenging eNOS decreases the production of NO thereby carrying an inhibiting effect on angiogenesis.

In a preferred embodiment of the invention said partial amino acid sequence comprises the caveolin-1 scaffolding domains A and/or B (described in the following sequences SEQ ID NO 2 and SEQ ID NO 3) or portions thereof able to bind selectively upon the endothelial isoform of nitric oxide synthase (eNOS). The inventors reported previously that the coimmunoprecipitation of eNOS with caveolin is completely and specifically blocked by an oligopeptide corresponding to the caveolin scaffolding domain (Michel et al. 1997). Peptides corresponding to this domain markedly inhibit NO synthase activity. This inhibition is competitive and completely reversible by Ca²⁺-calmodulin. The use of these peptides have been suggested to regulate eNOS activity but never linked to a possible effect on angiogenesis. As caveolin-1 is a peptide (nucleotide sequence enclosed see SEQ ID NO 1), said analogs or compounds can be derivatives of said peptide, peptidomimetics or homologous peptides that comprise the deletion or the replacement of one or more amino acids in the original caveolin-1 sequence, or antibodies directed against the ligand binding site epitopes of the active site(s) upon the endothelial isoform of nitric oxide synthase, or anti-idiotypic antibodies directed against particular antibodies directed against the specific portions of caveolin-1 (scaffolding domain A and/or B of caveolin-1 (SEQ ID NO 2 and SEQ ID NO 3) binding the active site(s) (of caveolin-1) upon the endothelial isoform of nitric oxide synthase. Said antibodies can be raised to caveolin-1 fragments and analogs both in the unnatural occurring form or in the unrecombined form.

The present invention also relates to a pharmacological composition for use as a medicament for the modulation of angiogenesis comprising a compound or a pharmaceutically acceptable derivative thereof. The composition according to the invention

is characterized in that it contains a compound that may vary according to the mode of administration.

Said suitable pharmaceutical carrier or adjuvant is a common pharmaceutical carrier or adjuvant well known by the person skilled in the art and used to increase or modulate the therapeutical and/or prophylactic effects of the active compounds according to the invention and/or to decrease the possible side effects of said compound(s).

5 The pharmaceutical composition according to the invention is prepared according to the methods generally applied by pharmacists and may include solid or liquid non-toxic and pharmaceutically acceptable carrier(s) or vehicle(s).

10 The percentage of active product / pharmaceutically suitable carrier can vary within very large ranges, only limited by the tolerance and the level of the habit forming effects
10 of the composition to the mammal (including the human). These limits are particularly determined by the frequency of administration.

15 The present invention relates to the use of a compound optionally combined with a suitable excipient, for the treatment of angiogenesis related diseases such as angiogenesis-dependent tumour growth and metastatic diseases, ischemic heart and peripheral vascular diseases including cerebral diseases and wound healing. The decrease or
15 the increase of nitric oxide results in a modification of neo-angiogenesis which has prophylactic or therapeutic properties in specific pathologies and diseases of mammals (including the human), and preferably selected from the group consisting of: high blood pressure, cardiac insufficiency, cardiac decompensation, ischemic cardiomyopathy, dilated or post-transplantation cardiomyopathies, angina pectoris (including instable angina), coronary spasm, post-transplantation coronaropathy, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, vascular side effects of diabetes melitus (insulino-dependent or not), vascular side effects of chronic renal insufficiency (uremia), endothelial dysfunction of various origins (atherosclerosis, smoke-addiction, syndrome X, obesity, hypertension, dyslipidemia, resistance to insulin), systemic or auto-immune vasculitis, hyperhomocysteinemia, buerger angeitis, post-angioplasty coronary restenosis, peripheral vascular disease, thrombo-embolic disease, deep or superficial vein thrombosis, atherosclerosis with arterial insufficiency in a vascular area (ischemia, including cerebral ischemia, coronary ischemia → pulmonary arterial hypertension, side effects of home

20 tumours → liver cirrhosis, liver metastases (metastasis proliferation), resistance of malignant neoplastic tumours to radio or chemotherapy, bladder cancer metastatic or not

(cystadenocarcinoma), angiosarcoma, proliferative retinopathies, wound healing or a mixing thereof. For cancer treatment inhibition of this angiogenesis is required and therefore increase of caveolin-1 is pursued. Contrary to the present invention WO99/46592 targets proliferating cells by transfecting caveolin-1 cDNA to increase cholesterol efflux and consecutively decrease mitosis. The present invention is focused by the fact that it promotes the increase in caveolin-1 in endothelial cells (for instance through an increase in cell cholesterol) to reduce endothelial NO production and tumour angiogenesis.

In particular, the present invention also provides a diagnostic kit for the testing of a compound or a composition for their ability to modulate angiogenesis via the intracellular free cholesterol-caveolin1-eNOS-NO pathway.

The present invention describes a method for screening compounds or compositions which modulate angiogenesis via the intracellular free cholesterol-caveolin1-eNOS-NO pathway.

The present invention relates also to a method to manufacture a medicament for the modulation of angiogenesis comprising as described above.

In addition, the present invention illustrates a method of treating a subject in the need of influencing angiogenesis by administering an angiogenesis-modulating-compound according to claims 1 to 23 in a sufficient concentration able to modulate angiogenesis within this subject.

The present invention also relates to the use of a compound for the modulation of the cholesterol synthesis, influx, efflux and/or metabolism, in a cell in vitro, in vivo or ex vivo.

The present invention also relates to the use of a compound for the modulation of the expression/activity of caveolin-1 in a cell in vitro, in vivo or ex vivo.

The present invention also relates to the use of a compound for the modulation of the expression/activity of eNOS in a cell in vitro, in vivo or ex vivo.

The present invention also relates to the use of a compound for the modulation of the expression/activity of a protein involved in the cholesterol metabolism in a cell in vitro, in vivo or ex vivo.

The following examples and figures merely serve to illustrate the invention and are by no way to be understood as limiting the present invention

Brief description of the figures

5

Figure 1. Effect of LDL-Chol on caveolin-1, eNOS proteins expression and their interaction in EC. Changes in caveolin-1 (upper lane) and eNOS (middle lane) abundance analysed by immunoblotting (IB), and in the amount of eNOS co-immunoprecipitated (IP) with caveolin (lower lane) are shown. Blots are representative of 3-5 separate experiments.

10

Figure 2. Concentration-dependent effect of atorvastatin on caveolin-1 and eNOS expression at various levels of LDL-Chol (0, 100 and 200 mg/dl). **A.** Immunoblotting (IB) analyses of caveolin-1 (left panel) and eNOS (right panel) abundance are shown. **B.** Densitometric analyses of caveolin immunoblots ($n=3-4$) as illustrated in panel A.

15

Figure 3. Differential sensitivity of caveolin-1 expression to cholesterol uptake and synthesis. Upper panel: Comparison of the effects of atorvastatin (1 $\mu\text{mol/L}$) or ALLN (25 $\mu\text{mol/L}$), an inhibitor of SREBP catabolism, on caveolin abundance in EC incubated in absence or in presence of LDL-Chol. Lower panel: Reversal by mevalonate of the reduction in caveolin abundance induced by atorvastatin, but not ALLN. Caveolin immunoblots (cav-1 IB) are representative of 2-3 separate experiments.

20

Figure 4. Atorvastatin decreases the inhibitory interaction of eNOS with caveolin and enhances NOS activity. EC were incubated in presence of 100 mg/dl LDL-Chol with or without atorvastatin. **A.** Effects of atorvastatin on the amount of eNOS co-immunoprecipitated with caveolin (cav-1 IP, upper lane); residual eNOS immunoprecipitated by eNOS antibodies (eNOS IP, lower lane) was also measured in the caveolin IP supernatant (Spnt). eNOS immunoblots (eNOS IB) are representative of 3 separate ex-

periments. **B.** Atorvastatin increases eNOS catalytically active NOS production determined (in native conditions) in absence of atorvastatin, and represent the mean \pm SEM of 3 separate ex-

periments ($\delta P < 0.05$, $*P < 0.01$, vs corresponding values in absence of atorvastatin treatment).

Figure 5. Atorvastatin differentially increased basal and agonist-stimulated NO production in intact EC. **A.** Measurements of basal NOx production from intact EC exposed to increasing concentrations of atorvastatin and/or LDL-Chol. **B.** Effects of atorvastatin (0.1 $\mu\text{mol/L}$) on A23187-induced acute NO release (over 5 min-period, measured with an amperometric probe). Data are expressed in % of L-NAME-inhibitable NOx production (panel A) or NO release (panel B) determined in absence of LDL-Chol and atorvastatin; means \pm SEM are representative of 3 separate experiments. **C.** Schematic representation of the relationship between extracellular LDL-chol and the restoration of NO production by atorvastatin (0.1 $\mu\text{mol/L}$) (relative to untreated cells) for basal versus stimulated eNOS activity. $*P < 0.01$, vs corresponding values in absence of atorvastatin treatment.

15

Figure 6. Atorvastatin differentially promotes the eNOS/Hsp90 interaction in EC incubated in absence or in presence of 200 mg/dl LDL-Chol. Immunoprecipitations were performed with eNOS antibodies (eNOS IP) from lysates of non-stimulated cells or at 30 min following an initial 5-min stimulation with A23187. Immunoprecipitates (upper lane) and lysates (lower lane) were immunoblotted with Hsp90 antibodies (Hsp90 IB). Blots are representative of 2 separate experiments.

Figure 7: **A.** Pavimentous organization of endothelial cells cultured on dishes. **B.** Tube formation in the « 3D » Matrigel model. **C.** Tube formation in the « sandwich » Matrigel model. **D.** Inhibition of tube formation in caveolin-overexpressing endothelial cells in the « sandwich » model.

Modes for carrying out the invention:

Example 1:

HMGCoA reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. The inventors provided biochemical and functional evidence that atorvastatin promotes NO production by decreasing caveolin-1 expression in EC, regardless of the level of extracellular LDL-Cholesterol. These findings highlight the therapeutic potential of inhibiting cholesterol synthesis in peripheral cells to correct NO-dependent endothelial dysfunction associated with hypercholesterolemia and possibly, other diseases.

METHODS.

Cell culture and treatments.

Human low-density lipoprotein (LDL) subfractions and lipoprotein-deprived serum (LPDS) were prepared as previously described (Feron et al. 1999). Freshly prepared LDL subfractions were supplemented with 50 µmol/L diethylenetriaminepentaacetic acid (DTPA) and used to prepare stock media at final concentrations of 100 and 200 mg/dl cholesterol.

Bovine aortic EC (BAEC) were cultured to confluence in 3.5 cm dishes in DMEM containing 10% serum and were serum-starved for 24 hours. Cell monolayers were then exposed for 48 hours to atorvastatin (10 nmol/L-10 µmol/L) in DMEM containing (or not) LDL subfraction. Incubations were carried out in presence of 100 µg/mL Cu/Zn superoxide dismutase (SOD) and medium was replaced every 12 hours. In some experiments, incubations were carried out in the presence of 1mmol/L mevalonate (Sigma) or 25 µmol/L N-acetyl-leu-leu-norleucinal (ALLN) (Boehringer Mannheim).

Immunoprecipitation and immunoblotting.

EC were collected and homogenized in an octylglucoside-containing buffer, and processed for immunoblotting or immunoprecipitation as described previously (Feron et al. 1999). Steady-state levels of caveolin-1 were measured in the presence of 0.4 mM EGTA + 1 mM and 20 µmol/L sodium molybdate as reported by Bender et al. (1999).

NO_x measurements and NO detection.

Quantitative analysis of nitrate and nitrite (NO_x) was used as an index of NO production in the different cell systems. Briefly, aliquots of the medium bathing intact EC or cell lysates were collected at different time intervals and processed through a cadmium-based microreductor chamber (WPI, Aston, U.K.) to quantitatively reduce nitrate to nitrite. Acidic iodide was then used to convert nitrite to NO that was electro-chemically measured with an NO-selective microsensor (WPI), as recommended by the manufacturer. In some experiments, agonist-stimulated NO release was directly monitored by the NO sensor positioned above intact cell monolayers, as previously described (Feron et al., 1999). All the experiments were carried out in presence of 7.5 U/mL SOD and adequate controls using either vehicle or NOS inhibitors were routinely performed in parallel. Data are normalized for the amount of protein in the dish or in the lysate, and are presented for convenience as mean \pm SEM. Statistical analyses were made using Student's t test or one-way ANOVA where appropriate.

RESULTS.**LDL-Cholesterol upregulates caveolin and its interaction with eNOS in quiescent EC.**

By exposing confluent, serum-starved EC for 48 hours to culture medium containing or not LDL subfractions isolated from human serum (100 or 200 mg/dl cholesterol content), the present inventors examined the extent of the modulatory effect of LDL-Cholesterol (LDL-Chol) on caveolin abundance and caveolin/eNOS interaction. As in the previous study using non-serum-starved EC (Feron et al. 1999), the inventors found that while eNOS expression was not altered by the different treatments, caveolin protein expression dose-dependently increased with the levels of LDL-Chol present in the culture medium (Figure 1). In parallel to the increase in caveolin abundance, the association between both proteins, as reflected by the fraction of eNOS immunoprecipitated by

HMGCoA reductase inhibition leads to a reduction in caveolin expression

The inventors next examined the effects of a reduction in intracellular cholesterol neo-synthesis on the same parameters. Cells were incubated for 48 hours in absence of extracellular LDL-Chol but with increasing doses of the HMGCoA reductase inhibitor 5 atorvastatin. As depicted in Figure 2A (left panel, upper lane), the present inventors observed a dramatic reduction in caveolin expression already with the lowest dose used in this study (-75 ± 13 % with 0.01 µmol/L atorvastatin; P < 0.01, n = 3).

In order to examine whether the effect of atorvastatin on caveolin expression was maintained in the presence of an extracellular source of cholesterol, the inventors 10 repeated the above experiments with EC exposed to either 100 mg/dl or 200 mg/dl LDL-Chol. In cells exposed to 100 mg/dl LDL-chol, the inventors observed a dose-dependent inhibitory effect of atorvastatin on caveolin expression (Figure 2A, left panel, middle lane). At 200 mg/dl LDL-Chol (Figure 2A, left panel, lower lane), despite the higher starting level of caveolin expression, a reduction in caveolin abundance was clearly detectable (see frame in Figure 2A, left panel). Furthermore, when densitometric analyses 15 of immunoblots were performed on exposure-matched films, the absolute decrease in caveolin abundance was not significantly different in each LDL-Chol condition tested (Figure 2B). Importantly, atorvastatin (up to 1µmol/L) did not induce any significant increase in eNOS abundance, which was only observed at the highest dose of the drug 20 (10 µmol/L) (Figure 2A, right panel).

Caveolin expression is regulated by endogenous cholesterol synthesis and the transcriptional factor SREBP.

To examine whether these effects of atorvastatin were directly mediated through 25 inhibition of cholesterol neo-synthesis which could transcriptionally regulate caveolin expression through sterol regulatory elements (SRE) present in its promoter region (Bist et al. 1997), two complementary sets of experiments were designed. First, EC incubated in

the absence of extracellular cholesterol were treated with increasing doses of atorvastatin and ALLN. Atorvastatin and ALLN inhibited caveolin expression to a similar level (Figure 3, upper panel).

By contrast, when cells were exposed to 200 mg/dl LDL-Chol, atorvastatin did reduce caveolin expression but to a lesser extent than ALLN whereas at 100 mg/dl LDL-Chol, the effect of atorvastatin was intermediary (see Figure 3, upper panel). In subsequent series of experiments, the present inventors examined if mevalonate, the downstream product of HMGCoA reductase, reversed these effects. As shown in Figure 3 (lower panel), while mevalonate had no effect on the repression of caveolin expression by ALLN, it completely reversed the inhibitory effect of atorvastatin on the expression level of caveolin in every condition tested, and even led to an increase over basal amounts of caveolin in some experiments (compare for instance lanes 1 and 2 or 7 and 8 in Figure 3, lower panel).

HMGCoA reductase inhibition leads to a reduction in the inhibitory caveolin/eNOS interaction in EC and promotes NO production.

The inventors previously demonstrated, in the same model (Feron et al, 1999), that the extent of caveolin/eNOS interaction is proportional to the abundance of caveolin (see also Figure 1). Therefore, the inventors next verified whether the effect of atorvastatin on caveolin expression was associated with a reduction in its association to eNOS, in absence of any detectable change in eNOS abundance. Figure 4A (upper panel) shows that, upon co-incubation with 0, 0.1 or 1 μ mol/L atorvastatin and 100 mg/dl LDL-Chol, atorvastatin reduced the amounts of eNOS bound to caveolin in EC, as reflected by the extent of eNOS co-immunoprecipitated by caveolin antibodies. Accordingly, more free, unbound eNOS found was found in the supernatant of the co-immunoprecipitation (Figure 4A, lower panel).

The present inventors also examined whether these changes in the extent of caveolin/eNOS interaction directly accounted for changes in eNOS activity in the same conditions. Therefore, the inventors measured eNOS activity from total lysates and caveolin IP supernatants, i.e. in caveolin-depleted lysates. As shown in Figure 4B, atorvastatin treatment led to a significant increase in NO_x production in the same proportion

HMGCoA reductase inhibition increases both basal and stimulated eNOS activity in intact cells.

The inventors next determined whether the decrease in caveolin abundance following statin treatment was paralleled with increases in basal and stimulated eNOS activity in intact EC. Basal eNOS activity measured from cells exposed to LDL-free medium was 0.98 ± 0.12 nmol/h/ 10^6 cells ($n=6$). In this condition, co-incubation with increasing doses of atorvastatin produced a 45-60%-increase at concentrations between 0.01-1 $\mu\text{mol/L}$ and a further 35%-increase at the highest drug concentration (10 $\mu\text{mol/L}$) (Figure 5A, black bars). Of note, when cells were co-incubated with mevalonate, statin exposure failed to induce any increase in basal NOx production (not shown). In absence of drug treatment, the 48h-incubation in presence of 100 or 200 mg/dl LDL-Chol led to an average 25 and 53 % decrease in basal NOx production (Figure 5A). When cells were co-incubated with atorvastatin, the present inventors observed a restoration of basal NOx production in cells exposed to the lower dose of LDL-Chol (100 mg/dl) but no significant increase in basal eNOS activity in cells exposed to 200 mg/dl LDL-Chol (Figure 5A).

The present inventors next examined the effect of atorvastatin on agonist-evoked eNOS activation. EC were pre-incubated or not with LDL-Chol and/or atorvastatin, and then exposed for 5 min to the calcium ionophore A23187 (5 $\mu\text{mol/L}$), a receptor-independent agonist known to promote the binding of Ca^{2+} -activated calmodulin to eNOS (Feron et al. 1999; Feron et al. 1998b). In absence of atorvastatin (Figure 5B, open bars), cell exposure to extracellular LDL-Chol led to a dramatic decrease in A23187-stimulated NO release consistent with the higher levels of caveolin and its inhibitory interaction with eNOS. Atorvastatin treatment (0.1 $\mu\text{mol/L}$) increased the level of agonist-induced NO release but the relative extent of this augmentation (see Figure 5B, black bars) greatly differed in each condition tested, i.e. from 5% in cells not exposed to LDL-Chol up to 17 and 107% in cells co-incubated with 100 and 200 mg/dl

Figure 5 illustrates the inverse relationship between extracellular LDL Chol and the restoration of NO production by atorvastatin for basal versus stimulated eNOS activ-

ity, i.e. the effect of 0.1 $\mu\text{mol/L}$ atorvastatin on basal NO production was most prominent at low extracellular cholesterol whereas the drug was most effective to potentiate agonist-evoked NO release at high LDL-Chol.

5 **HMGCoA reductase inhibition promotes eNOS/Hsp90 interaction.**

The data presented in Figure 5B prompted the inventors to examine whether long-term activation of eNOS led to similar differences. The inventors therefore measured the amounts of NOx accumulated in the extracellular medium of EC during 30 min following a 5-min exposure to A23187 (and extensive washing). At 200 mg/dl LDL-Chol, 10 the effect of atorvastatin was even more pronounced (than upon acute NO release, see Fig. 5B) with the NOx accumulation reaching ~500% of the value observed in absence of the statin, while NOx production increased to 1.2 and 1.6-fold the control value at 0 and 100 mg/dl LDL-chol, respectively (not shown).

Hsp90 has been proposed to act as a molecular chaperone facilitating long-term 15 activation of eNOS (Garcia-Cardena et al., 1998). The inventors therefore compared the amount of Hsp90 co-immunoprecipitated by eNOS antibodies from lysates of cells incubated or not with atorvastatin, in presence or in absence of LDL-Chol.

The present inventors first confirmed that Hsp90/eNOS interaction was promoted upon agonist stimulation, as shown by the increased amount of Hsp90 detected in the 20 eNOS immunoprecipitate from lysates of A23187-simulated EC (see lanes 1 and 3 in Figure 6, upper panel). Of interest, atorvastatin promoted the interaction between Hsp90 and eNOS at the basal level, in EC exposed or not to high LDL-cholesterol (see Figure 6, lanes 5 and 6, and 1 and 2, respectively). More importantly, the data show that upon stimulation with calcium ionophore, the Hsp90/eNOS interaction was minimally influenced by atorvastatin in the absence of LDL-cholesterol (see Figure 6, lanes 3 and 4), but increased five-fold by atorvastatin in the presence of 200 mg/dl LDL-cholesterol in the extracellular medium (see Figure 6, lanes 7 and 8). There was no change in total Hsp90 expression in any condition (Figure 6, lower panel), suggesting 25

The inventors identified a cholesterol-dependent mechanism of endothelial dysfunction that involves the post-translational regulation of eNOS in the absence of changes in absolute eNOS abundance. Instead, cholesterol modulates the abundance, in EC, of caveolin-1 that acts as an inhibitor of eNOS activation. Importantly, this study
5 shows that the HMGCoA reductase inhibitor, atorvastatin, restores eNOS activity through downregulation of caveolin-1 expression. This occurs at concentrations as low as 10-100 nmol/L, and is fully reversed by addition of excess mevalonate, confirming the drug's specific effect on the mevalonate pathway. Recent studies had highlighted the therapeutic potential of inhibiting the mevalonate pathway in peripheral cells through the reduction of downstream isoprenoid intermediates, regardless of statins' effect on cholesterol neosynthesis. By contrast, the results directly implicate the inhibition by atorvastatin of cholesterol synthesis in EC as the mechanism promoting NO release. This is consistent with the previous identification of SRE in the promoter sequence of the caveolin-1 gene (Bist et al., 1997) and the observation that ALLN, an inhibitor of SREBP catabolism,
10 fully abrogates caveolin-1 expression in cultured EC.
15

Atorvastatin treatment potentiated both basal and agonist-stimulated NO production. The use of SOD and the receptor-independent calcium ionophore, A23187 ruled out indirect effects on NO oxidation or endothelial receptor coupling to eNOS, respectively. Of note, the statin was effective both in the absence and in the presence of exogenously added LDL-cholesterol, but with different efficiency in resting or stimulated cells (see Fig. 5C). This is best rationalized in terms of the reciprocal and competitive binding of either caveolin or calcium-calmodulin on eNOS to determine its activation. In unstimulated cells, i.e. at low activated calcium-calmodulin levels, eNOS activity is expected to be mainly determined by the abundance of caveolin available for its inhibitory binding to eNOS. In this condition, the effect of atorvastatin on NO production is proportional to its reduction of total caveolin. Accordingly, the inventors observed a stronger potentiation of basal NO release at zero extracellular LDL-cholesterol, i.e. when the (low) caveolin pool is maximally sensitive to inhibition of endogenous cholesterol
20 synthesis (cf. Fig. 5A, B). This is reinforced in agonist-stimulated cells, in which acti
25

The latter effect is reversed in the presence of exogenous LDL-cholesterol, however, agonist-stimulation of eNOS activity may be more critically affected by subtle

changes in total caveolin abundance, such as those observed with atorvastatin at 200 mg/dl LDL-C (see Fig. 5B). These small changes may be sufficient to alter the enzyme's ability to interact with other modulators as well, as demonstrated with the chaperone hsp90 in the present study, resulting in substantial increases in eNOS sensitivity. More generally, present demonstration of atorvastatin's effect to decrease caveolin-1 expression leaves additional possibilities to impact on disease processes involving the interaction of caveolin with a variety of signaling molecules, e.g. tyrosine kinases, adenylyl cyclase or G-protein coupled receptors (Smart et al. 1999).

10 Clinical implications

A deficient NO-dependent vasorelaxation is central to coronary and peripheral ischemic diseases secondary to hypercholesterolemia and may result from either a decreased production of NO or an increase in NO catabolism (Wever et al. 1998). Interestingly, both processes can be restored by supplementation with L-arginine or tetrahydrobiopterin *in vivo* (for refs see Wever et al, 1998), suggesting that eNOS is still expressed in the dysfunctional endothelium, but somehow inactivated. In this regard, the eNOS "sensitizing" effect of atorvastatin may already operate at very early stages of endothelial dysfunction, at a time when the enzyme's activation (but not abundance) is downregulated. Present results demonstrates that this peripheral effect can occur at 20 very low concentrations of the drug, i.e. close to those achieved therapeutically *in vivo*. In addition, the observation of a marked potentiation of basal NO production at zero extracellular LDL-cholesterol may extend the clinical usefulness of atorvastatin (and perhaps other statins as well) to NO-dependent endothelial dysfunctions secondary to diseases other than hypercholesterolemia, such as hypertension or heart failure.

25

Example 2:

The inventors have developed different techniques to evaluate angiogenesis *in vitro* and used some of them to test the possibility to modulate NO-dependent angiogenesis by atorvastatin.

Endothelial cells are known to form tube-like structures when cultured within gels of collagen, fibrin or Matrigel®. Accordingly, in the "3-D model", endothelial

cells are mixed to the matrix before gelification and tube-like structures are obtained after 48-72 hours (Figure 7B); this model, however, reduces the efficiency of transfection. In the "sandwich model", cells are first cultured to confluence on a first layer of matrix, and are then covered by a second matrix layer; cells are easily transfected in the 5 interval preceding the addition of the upper layer. The latter technique allows the formation of endothelial tubes in 3-6 hours; the tube structures are mature 12 hours after induction (Figure 7C) and then start to regress.

When endothelial cells were first transfected with a caveolin-encoding vector (24 hours before addition of the second matrix layer), the formation of tube structures was 10 dramatically inhibited (Figure 7D). Importantly, SNAP, a NO donor agent, was shown to correct this anti-angiogenic effect observed in caveolin-overexpressing cells. Yet, in non-transfected cells, both SNAP and the HMGCoA reductase inhibitor atorvastatin accelerated the endothelial tube formation in this model of in vitro angiogenesis. Also, in the same model, NOS inhibitors were shown to mimick the effect of caveolin overexpression, i.e. by slowing down the tube formation. Of note, when endothelial cells were 15 transfected with an irrelevant construct (β -galactosidase-encoding), no change in the rate and extent of tube formation was observed.

Finally, atorvastatin was shown to promote NO production (see example 1) in the same cells (bovine aortic endothelial cells) by decreasing caveolin abundance. The inventors therefore interpret the observed promoting effect of statins on tube formation 20 by this effect on caveolin abundance.

Example 3:

The inventors have also developed techniques to evaluate angiogenesis ex vivo 25 and used them to test the possibility to modulate NO-dependent angiogenesis by altering caveolin abundance.

Rat/mice aorta or arteries from fresh human umbilical cords are dissected and imbedded in a fibring gel. Endothelial cells are observed to migrate from the ends of the vessels and organize into tubules after 5-7 days.

Endothelial cell proliferation rates were significantly higher (+53%) than in control experiments. Interestingly, this effect was completely blocked by co-incubation with NOS in-

hibitors. Combined with the higher levels of caveolin in aortic endothelial cells exposed to atorvastatin, the inventors interpret the positive effect of statins on the tube outgrowth by the cholesterol-caveolin-eNOS-NO pathway described above.

5 **Example 4:**

The inventors have also developed techniques to evaluate angiogenesis *in vivo* and will use them to test the possibility to modulate NO-dependent angiogenesis by altering caveolin abundance.

10 The Chick chorioallantoic membrane (CAM) assay models the angiogenic process in the developing chick using the accessible chorioallantoic membrane with its developing network of blood vessels. When the CAM appears on day 7 after fertilization, statins can be implanted to modulate vessels growth.

15 In these different assays, lipophilic and more hydrophilic statins will be used at doses known to be reached therapeutically (10 nM-100 µM). Experiments will first be performed in the presence or the absence of NOS inhibitors to validate the existence of a NO-mediated angiogenic process in these models. The inventors will then examine the effects of statins on caveolin abundance by Western Blotting and consecutively, on eNOS activability by measuring the level of interaction of the enzyme with caveolin in co-immunoprecipitation experiments, as well as by determining the amounts of nitric 20 oxide released in each condition.

REFERENCES

- Bender AT, Silverstein AM, Demady DR et al. Neuronal nitric-oxide synthase is regulated 25 by the Hsp90-based chaperone system *in vivo*. J Biol Chem. 1999;274:1472-1478.
Bist A, Fielding PE, Fielding CJ. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Proc Natl Acad Sci U S A. 1997;94:10693-10698.
Byington RP, Jukema JW, Salonen TT et al. Reduction in cardiovascular events during 80-84 years of follow-up in a population cohort. Circulation. 1995;92:2419-2423.

- Corsini A, Pazzucconi F, Arnaboldi L et al. Direct effects of statins on the vascular wall. *J Cardiovasc Pharmacol.* 1998;31:773-778.
- Dunzendorfer S, Rothbucher D, Schratzberger P et al. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. *Circ Res.* 1997;81:963-969.
- Essig M, Nguyen G, Prie D et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. *Circ Res.* 1998;83:683-690.
- Feron O., Belhassen L., Kobzik L., Smith TW., Kelly RA. & Michel T. Endothelial nitric oxide synthase targeting to caveolae: specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. *J Biol Chem.* 1996;271, 22810-22814.
- Feron O., Michel JB., Kazu S. & Michel T. Dynamic regulation of eNOS: complementary roles of dual acylation and caveolin interactions. *Biochemistry* 1998a;37:193-200.
- Feron O, Saldana F, Michel JB et al. The endothelial nitric-oxide synthase-caveolin regulatory cycle. *J Biol Chem.* 1998b;273:3125-3128.
- Feron O., Dessy C., Opel DJ., Arstall MA., Kelly RA. & Michel T. Modulation of the eNOS-caveolin interactions in cardiac myocytes: implications for the autonomic regulation of heart rate. *J Biol Chem.* 1998c;273, 30249-30254.
- Feron O, Dessy C, Moniotte S et al. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. *J Clin Invest.* 1999;103:897-905.
- Fielding CJ, Fielding PE. Intracellular cholesterol transport. *J Lipid Res.* 1997;38:1503-1521.
- Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, Lisanti MP, Sessa WC. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the noscaveolin binding domain in vivo. *J Biol Chem.* 1997;272:5437-25440.
- Garcia-Cardena G, Fan R, Shah V et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. *Nature* 1998;392:821-824

- Guijarro C, Blanco-Colio LM, Ortego M et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. *Circ Res.* 1998;83:490-500.
- Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. *J Clin Invest.* 1998;101:2711-2719.
- Hidaka Y, Eda T, Yonemoto M et al. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). *Atherosclerosis.* 1992;95:87-94.
- Kaesemeyer WH, Caldwell RB, Huang J et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. *J Am Coll Cardiol.* 1999;33:234-241.
- Laufs U, La F, V, Plutzky J et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. *Circulation.* 1998;97:1129-1135.
- Liu J, Razani B, Tang S, Terman BI, Ware JA, Lisanti MP. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. *J Biol Chem.* 1999;274:15781-5.
- MAAS: the Multicentre Anti- Atheroma Study: Effect of simvastatin on coronary atheroma. *Lancet.* 1994;344:633-638.
- Maron DJ, Fazio S, Linton MF. Current perspectives on statins. *Circulation.* 2000;101:207-213.
- Michel JB., Feron O., Sacks D. & Michel T. Reciprocal regulation of endothelial nitric oxide synthase by Ca^{2+} -calmodulin and caveolin. *J Biol Chem.* 1997a;272:15583-15586.
- Michel JB., Feron O., Prabhakar P., Sase K. & Michel T. Caveolin versus calmodulin: counterbalancing allosteric regulators of endothelial nitric oxide synthase. *J Biol Chem.* 1997b;272:25907-25912.
- Michel T & Feron O. Nitric oxide synthase which also contains calmodulin, is improved by simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. *Circulation.* 1997;95:1126-1131.

- Rogler G, Lackner KJ, Schmitz G. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. *Am J Cardiol.* 1995;76:114A-116A.
- Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med.* 1996;335:1001-1009.
5
- Smart EJ, Graf GA, McNiven MA et al. Caveolins, liquid-ordered domains, and signal transduction. *Mol Cell Biol.* 1999;19:7289-7304.
- Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M Improvement of NO-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. *Arterioscler Thromb Vasc Biol* 2000;20:61-9.
10
- Wever RM, Luscher TF, Cosentino F et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. *Circulation* 1998;97:108-112.
- Williams JK, Sukhova GK, Herrington DM et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. *J Am Coll Cardiol.*
15
- 1998;31:684-691.

CLAIMS

1. A compound for use as a medicament for the modulation of angiogenesis through the tackling of the intracellular free cholesterol-caveolin1-eNOS-NO pathway.
5
2. A compound according to claim 1 for use as a medicament for the modulation of angiogenesis wherein said compound has its angiogenic effect via:
 - the modulation of the cholesterol metabolism and/or flux, and/or
 - the modulation of the caveolin-1 abundance/activity, and/or,
 - 10 - the modulation of the eNOS abundance/activity, and/or,
 - the modulation of the calmodulin abundance/activity, and/or,
 - the modulation of the Hsp90 abundance/activity, and/or,
 - the modulation of the NO production.
- 15 3. A compound according to claims 1 or 2 for use as a medicament for the modulation of angiogenesis, wherein said compound modulates intracellular free cholesterol by acting on cholesterol synthesis, cholesterol metabolism, cholesterol influx or cholesterol efflux.
- 20 4. A compound according to any of the claims 1 to 3 for use as a medicament for the modulation of angiogenesis, wherein said compound influences cholesterol metabolism and decreases caveolin-1 abundance and is chosen from the group comprising HMGCoA reductase inhibitors or a pharmacologically acceptable derivative thereof.
- 25 5. A compound according to claim 4 for use as a medicament for the modulation of angiogenesis wherein said HMGCoA reductase inhibitor is chosen from atorvastatin,

7. A compound according to any of the claims 1 to 3 for use as a medicament for the modulation of angiogenesis, wherein said compound influences cholesterol metabolism and increases caveolin-1 abundance, is chosen from a group comprising ACAT inhibitors or a pharmacologically acceptable derivative thereof.

5

8. A compound according to claim 7 for use as a medicament for the modulation of angiogenesis wherein said ACAT inhibitor is chosen from the group comprising avasimibe, NTE122, compound 58-035, TS-962 and the bacterial product epicochlioquinone A.

10

9. A compound according to any of the claims 1 to 3 for use as a medicament for the modulation of angiogenesis wherein said compound increases the export of cholesterol out of peripheral cells through the increased abundance of HDL particles resulting in the modulation of caveolin-1.

15

10. A compound according to claim 9 for use as a medicament for the modulation of angiogenesis which is chosen from a group comprising fenofibrate, bezafibrate and ciprofibrate.

20 11. A compound according to any of the claims 1 to 3 for use as a medicament for the modulation of angiogenesis wherein said compound decreases the production of cholesterol-rich VLDL particles by the liver.

25 12. A compound according to claim 11 for use as a medicament for the modulation of angiogenesis is chosen from the group comprising nicotinic acid.

13. A compound according to any of the claims 1 to 2 for use as a medicament for the modulation of angiogenesis wherein said compound influences abundance and/or activity of caveolin-1, eNOS, Hsp90 or calmodulin.

14. A compound according to any of the claims 1 to 3 for use as a medicament for the modulation of angiogenesis which consists of recombinant caveolin-1, recombinant eNOS, recom-

binant calmodulin, recombinant Hsp90 or a pharmacologically acceptable derivative thereof.

15. A compound according to claim 13 for use as a medicament for the modulation of angiogenesis which is a nucleic acid encoding the partial or total amino acid sequence of caveolin-1 or an analogue thereof which can increase the caveolin-1 concentration in the cell thereby increasing the scavenging of the endogenous eNOS.
16. A compound according to claim 13 for use as a medicament for the modulation of angiogenesis which is a nucleic acid encoding the partial or total amino acid sequence of eNOS or an analogue thereof which can increase the eNOS concentration and/or activity in the cell thereby increasing the production of intracellular NO.
17. A compound according to claim 13 for use as a medicament for the modulation of angiogenesis, which is able to change the concentration of endogenous caveolin-1, eNOS, calmodulin or Hsp90.
18. A compound according to claim 17 for use as a medicament for the modulation of angiogenesis, being an antisense nucleic acid able to hybridise with a corresponding nucleotide sequence encoding the caveolin-1 and antagonizes the expression of the caveolin-1 protein in the cell.
19. A compound according to claim 18 for use as a medicament for the modulation of angiogenesis, being an antisense nucleic acid as defined by SEQ ID NO 5.
20. A compound according to claim 13 for use as a medicament for the modulation of angiogenesis which consists of an antagonist or agonist of caveolin-1, eNOS, calmodulin or Hsp90.

25
where the antagonists or agonists are able to trap the endogenous caveolin-1 preventing its binding to the endothelial isoform nitric oxide synthase (eNOS).

22. A compound according to claim 13 and 20 for use as a medicament for the modulation of angiogenesis which is a nucleic acid encoding the partial or total amino acid sequence of eNOS or the eNOS sequence deleted or mutated in the active caveolin binding site or an analogue thereof which can increase the concentration of unbound (activated) eNOS.
- 5
23. A compound according to claim 22 for use as a medicament for the modulation of angiogenesis wherein said trapping molecule comprises an amino acid sequence pattern as described in SEQ ID NO 4, preferably comprising the amino acid sequence pattern as described in SEQ ID NO 6 to SEQ ID NO 86.
- 10
24. A compound according to claim 13 for use as a medicament for the modulation of angiogenesis, which is able to trap the endogenous eNOS preventing the formation of NO.
- 15
25. A compound according to claim 24 for use as a medicament for the modulation of angiogenesis wherein said partial amino acid sequence comprising the caveolin-1 scaffolding domains A and/or B as described in SEQ ID NO 2 and SEQ ID NO 3 or portions thereof able to bind selectively upon the endothelial isoform of nitric oxide synthase (eNOS).
- 20
26. A compound according to claim 24 for use as a medicament for the modulation of angiogenesis which is a nucleotide sequence encoding the partial or total amino acid sequence of caveolin or an analogue which can be used to decrease the unbound (inactivated) eNOS concentration in the cell.
- 25
27. A pharmacological composition comprising a compound according to any of the claims 1 to 26 or 28 to 31 which is acceptable as a starting material for the claimed

28. Use of a compound according to claims 1 to 26, optionally combined with a suitable excipient, for the treatment of angiogenesis related diseases such as angiogenesis-dependent tumour growth and metastatic diseases, ischemic heart and peripheral vascular diseases including cerebral diseases and wound healing.

5

29. Diagnostic kit for the testing of a compound or a composition for their ability to modulate angiogenesis via the intracellular free cholesterol-caveolin1-eNOS-NO pathway.

10 30. Method for screening compounds or compositions which modulate angiogenesis via the intracellular free cholesterol-caveolin1-eNOS-NO pathway.

31. Method to manufacture a medicament for the modulation of angiogenesis comprising a compound according to any of the claims 1 to 26.

15

32. Method of treating a subject in the need of influencing angiogenesis by administering an angiogenesis-modulating-compound according to claims 1 to 26 in a sufficient concentration able to modulate angiogenesis within this subject.

20 33. Use of a compound according to claims 1 to 26 for the modulation of the cholesterol metabolism in a cell in vitro, in vivo or ex vivo.

34. Use of a compound according to any of the claims 1 to 26 for the modulation of the expression of caveolin-1 in a cell in vitro, in vivo or ex vivo.

25

35. Use of a compound according to any of the claims 1 to 26 for the modulation of the expression of eNOS in a cell in vitro, in vivo or ex vivo.

36. Use of a compound according to any of the claims 1 to 26 for the modulation of the


37. Use of a compound according to any of the claims 1 to 26 for the modulation of the expression of Hsp90 in a cell *in vitro*, *in vivo* or *ex vivo*.


1/11

Figure 1.


LDL-Chol (mg/dl): 0 100 200

CAV-1 IB 


eNOS IB 

CAV-1IP/ eNOS IB 

2/11

Figure 2A.

3/11

Figure 2B.

4/11




Figure 3.

Figure 4A.


5/11




6 / 11

Figure 4B.


7/11

Figure 5A.


8/11

Figure 5B.


9/11

Figure 5C.

10/11

Figure 6.

11/11

Figure 7:

SEQUENCE LISTING

<110> UNIVERSITE CATHOLIQUE DE LOUVAIN

<120> USE OF COMPOUND OR PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND/OR THE TREATMENT OF ISCHEMIC HEART AND PERIPHERAL VASCULAR DISEASES, TUMOUR DEVELOPMENT AND FOR WOUND HEALING

<130> P.UCL.72/EP

<140>

<141>

<160> 86

<170> PatentIn Ver. 2.1

<210> 1

<211> 537

<212> DNA

<213> Homo sapiens

<400> 1

atgtctgggg gcaaataacgt agactcggag ggacatctct acaccgttcc catccgggaa 60
caggcaaca tctacaacgc caacaacaag gcccattggcag acggagcttag cgagaagcaa 120
gtgtacgacg cgcacaccaa ggagatcgac ctggtaacc gcgcacctaa acacacctaac 180
gtatcacgtgg tcaagattga ctttgaagat gtgattgeag aaccagaagg gacacacagt 240
tttcacggca tttggaaaggc cagcttcaacc accttcaactg tgacgaaata ctggttttac 300
cgcttgctgt ctgccttctt tgcatcccc atggcaactca tctggggcat ttacttgc 360
attctctctt tcctgcacat ctgggcagtt gtaccatgea ttaagagett ctgtattgag 420
attcaagtgc ccagccgtgt ctatccatc tacgtccaca ccgtctgtga cccactcttt 480
gaaagctgttg ggaaaatatt cagcaatgtc cgcataact tgcagaaaaga aatataa 537

<210> 2

<211> 20

<212> PRT

<213> Homo sapiens

<400> 2

His Gly Ile Trp Ile Ala Ser Phe Thr Thr Phe Thr Thr Val Asp Glu +

<210> 3
<211> 22
<212> PRT
<213> Homo sapiens

<400> 3
Lys Ser Phe Leu Ile Glu Ile Gln Cys Thr Ser Arg Val Tyr Ser Ile
1 5 10 15

Tyr Val His Thr Val Cys
20

<210> 4
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 4
Phe Pro Ala Ala Pro Phe Ser Gly Trp Tyr
1 5 10

<210> 5
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: partial
antisense sequence of human caveolin-1

<400> 5
gagtctacgt atttcccccc agacatgtcg gcccgtggct 40

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 6
Phe Xaa Phe Xaa Xaa Xaa Xaa Phe Xaa Phe
1 5 10

<210> 7
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 7
Phe Xaa Phe Xaa Xaa Xaa Xaa Phe Xaa Tyr
1 5 10

<210> 8
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 8
Phe Xaa Phe Xaa Xaa Xaa Xaa Tyr Xaa Tyr
1 5 10

<210> 9
<211> 10

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 9

Phe Xaa Tyr Xaa Xaa Xaa Xaa Tyr Xaa Tyr
1 5 10

<210> 10

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 10

Phe Xaa Trp Xaa Xaa Xaa Xaa Tyr Xaa Tyr
1 5 10

<210> 11

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 11

Phe Xaa Phe Xaa Xaa Xaa Xaa Trp Xaa Tyr
1 5 10

<210> 12

<211> 10

<212> PRT

<213> Artificial Sequence

<400> 12

Phe Xaa Tyr Xaa Xaa Xaa Xaa Trp Xaa Tyr

1

5

10

<210> 13
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 13
Phe Xaa Trp Xaa Xaa Xaa Xaa Trp Xaa Tyr
1 5 10

<210> 14
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 14
Phe Xaa Tyr Xaa Xaa Xaa Xaa Phe Xaa Tyr
1 5 10

<210> 15
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

1

5

10

<210> 16
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 16
Phe Xaa Phe Xaa Xaa Xaa Xaa Phe Xaa Trp
1 5 10

<210> 17
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 17
Phe Xaa Phe Xaa Xaa Xaa Xaa Tyr Xaa Trp
1 5 10

<210> 18
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 18
Phe Xaa Tyr Xaa Xaa Xaa Xaa Tyr Xaa Trp

<210> 19
<211> 10

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 19
Phe Xaa Trp Xaa Xaa Xaa Xaa Tyr Xaa Trp
1 5 10

<210> 20
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 20
Phe Xaa Phe Xaa Xaa Xaa Xaa Trp Xaa Trp
1 5 10

<210> 21
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 21
Phe Xaa Tyr Xaa Xaa Xaa Xaa Trp Xaa Trp
1 5 10

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 22
Phe Xaa Trp Xaa Xaa Xaa Xaa Trp Xaa Trp
1 5 10

<210> 23
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 23
Phe Xaa Tyr Xaa Xaa Xaa Xaa Phe Xaa Trp
1 5 10

<210> 24
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 24
Phe Xaa Trp Xaa Xaa Xaa Xaa Phe Xaa Trp
1 5 10

<210> 25

<220>
<223> Description of Artificial Sequence: caveolin

<400> 25

Phe Xaa Phe Xaa Xaa Xaa Xaa Tyr Xaa Phe
1 5 10

<210> 26

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 26

Phe Xaa Tyr Xaa Xaa Xaa Xaa Tyr Xaa Phe
1 5 10

<210> 27

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 27

Phe Xaa Trp Xaa Xaa Xaa Xaa Tyr Xaa Phe
1 5 10

<210> 28

<211> 10

<212> PRT

<213> Artificial Sequence

<400> 28

Phe Xaa Phe Xaa Xaa Xaa Xaa Trp Xaa Phe

1

5

10

<210> 29

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 29

Phe Xaa Tyr Xaa Xaa Xaa Xaa Trp Xaa Phe
1 5 10

<210> 30

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 30

Phe Xaa Trp Xaa Xaa Xaa Xaa Trp Xaa Phe
1 5 10

<210> 31

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin

1 5 10

<210> 32
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 32
Phe Xaa Trp Xaa Xaa Xaa Xaa Phe Xaa Phe
1 5 10

<210> 33
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 33
Tyr Xaa Phe Xaa Xaa Xaa Xaa Phe Xaa Phe
1 5 10

<210> 34
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 34

~ ~ ~

<210> 35
<211> 1~

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 35

Tyr Xaa Phe Xaa Xaa Xaa Xaa Tyr Xaa Tyr
1 5 10

<210> 36

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif.

<400> 36

Tyr Xaa Tyr Xaa Xaa Xaa Xaa Tyr Xaa Tyr
1 5 10

<210> 37

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 37

Tyr Xaa Trp Xaa Xaa Xaa Xaa Tyr Xaa Tyr
1 5 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 38

Tyr Xaa Phe Xaa Xaa Xaa Xaa Trp Xaa Tyr
1 5 10

<210> 39

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 39

Tyr Xaa Tyr Xaa Xaa Xaa Xaa Trp Xaa Tyr
1 5 10

<210> 40

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 40

Tyr Xaa Trp Xaa Xaa Xaa Xaa Trp Xaa Tyr
1 5 10

<210> 41

<211> 10

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 41
Tyr Xaa Phe Xaa Xaa Xaa Xaa Phe Xaa Trp
1 5 10

<210> 42
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 42
Tyr Xaa Phe Xaa Xaa Xaa Xaa Tyr Xaa Trp
1 5 10

<210> 43
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 43
Tyr Xaa Tyr Xaa Xaa Xaa Xaa Tyr Xaa Trp
1 5 10

<210> 44
<211> 10
<212> PRT
<213> Artificial Sequence

<400> 44
Tyr Xaa Trp Xaa Xaa Xaa Xaa Tyr Xaa Trp

1

5

10

<210> 45
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 45
Tyr Xaa Phe Xaa Xaa Xaa Trp Xaa Trp
1 5 10

<210> 46
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 46
Tyr Xaa Tyr Xaa Xaa Xaa Xaa Trp Xaa Trp
1 5 10

<210> 47
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

1

5

10

<210> 48
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 48
Tyr Xaa Phe Xaa Xaa Xaa Xaa Tyr Xaa Phe
1 5 10

<210> 49
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 49
Tyr Xaa Tyr Xaa Xaa Xaa Xaa Tyr Xaa Phe
1 5 10

<210> 50
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 50

<210> 51

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin binding motif

<400> 51
Tyr Xaa Phe Xaa Xaa Xaa Trp Xaa Phe
1 5 10

<210> 52
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin binding motif

<400> 52
Tyr Xaa Tyr Xaa Xaa Xaa Xaa Trp Xaa Phe
1 5 10

<210> 53
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin binding motif

<400> 53
Tyr Xaa Trp Xaa Xaa Xaa Xaa Trp Xaa Phe
1 5 10

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 54

Tyr Xaa Tyr Xaa Xaa Xaa Xaa Phe Xaa Phe
1 5 10

<210> 55

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 55

Tyr Xaa Trp Xaa Xaa Xaa Xaa Phe Xaa Phe
1 5 10

<210> 56

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 56

Tyr Xaa Tyr Xaa Xaa Xaa Xaa Phe Xaa Tyr
1 5 10

<210> 57

<211> 10

<212> PRT

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 57

Tyr Xaa Trp Xaa Xaa Xaa Xaa Phe Xaa Tyr
1 5 10

<210> 58

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 58

Tyr Xaa Tyr Xaa Xaa Xaa Xaa Phe Xaa Trp
1 5 10

<210> 59

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 59

Tyr Xaa Trp Xaa Xaa Xaa Xaa Phe Xaa Trp
1 5 10

<210> 60

<211> 10

<212> PRT

<213> Artificial Sequence

<400> 60

Tyr Xaa Trp Xaa Xaa Xaa Xaa Phe Xaa Trp

1

5

10

<210> 61
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 61
Trp Xaa Phe Xaa Xaa Xaa Xaa Phe Xaa Tyr
1 5 10

<210> 62
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 62
Trp Xaa Phe Xaa Xaa Xaa Xaa Tyr Xaa Tyr
1 5 10

<210> 63
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin

Trp Xaa Tyr Xaa Ile Xaa Xaa Tyr Xaa Tyr
1 5 10

<210> 64

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 64

Trp Xaa Trp Xaa Xaa Xaa Xaa Tyr Xaa Tyr
1 5 10

<210> 65

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 65

Trp Xaa Phe Xaa Xaa Xaa Xaa Trp Xaa Tyr
1 5 10

<210> 66

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 66

<210> 67

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 67

Trp Xaa Trp Xaa Xaa Xaa Xaa Trp Xaa Tyr
1 5 10

<210> 68

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 68

Trp Xaa Phe Xaa Xaa Xaa Xaa Phe Xaa Trp
1 5 10

<210> 69

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 69

Trp Xaa Phe Xaa Xaa Xaa Xaa Tyr Xaa Trp
1 5 10

<211> 10

<212> PPT

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 70
Trp Xaa Tyr Xaa Xaa Xaa Xaa Tyr Xaa Trp
1 5 10

<210> 71
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 71
Trp Xaa Trp Xaa Xaa Xaa Xaa Tyr Xaa Trp
1 5 10

<210> 72
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 72
Trp Xaa Phe Xaa Xaa Xaa Xaa Trp Xaa Trp
1 5 10

<210> 73
<211> 10

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 73
Trp Xaa Tyr Xaa Xaa Xaa Xaa Trp Xaa Trp
1 5 10

<210> 74
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 74
Trp Xaa Trp Xaa Xaa Xaa Xaa Trp Xaa Trp
1 5 10

<210> 75
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 75
Trp Xaa Phe Xaa Xaa Xaa Xaa Tyr Xaa Phe
1 5 10

<210> 76
<211> 10
<212> PRT
<213> Artificial Sequence

<400> 76
Trp Xaa Tyr Xaa Xaa Xaa Xaa Tyr Xaa Phe

1

5

10

<210> 77

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 77

Trp Xaa Trp Xaa Xaa Xaa Xaa Tyr Xaa Phe
1 5 10

<210> 78

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 78

Trp Xaa Phe Xaa Xaa Xaa Xaa Trp Xaa Phe
1 5 10

<210> 79

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

Trp Xaa Tyr Xaa Xaa Xaa Xaa Trp Xaa Phe

5

10

<210> 80
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 80
Trp Xaa Trp Xaa Xaa Xaa Xaa Trp Xaa Phe
1 5 10

<210> 81
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 81
Trp Xaa Tyr Xaa Xaa Xaa Xaa Phe Xaa Phe
1 5 10

<210> 82
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 82
Trp Xaa Trp Xaa Xaa Xaa Xaa Phe Xaa Phe

<210> 83
<211> 10

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 83
Trp Xaa Tyr Xaa Xaa Xaa Xaa Phe Xaa Tyr
1 5 10

<210> 84
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 84
Trp Xaa Trp Xaa Xaa Xaa Xaa Phe Xaa Tyr
1 5 10

<210> 85
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: caveolin
binding motif

<400> 85
Trp Xaa Tyr Xaa Xaa Xaa Xaa Phe Xaa Trp
1 5 10

Artificial Sequence

<220>

<223> Description of Artificial Sequence: caveolin
binding motif

<400> 86

Trp Xaa Trp Xaa Xaa Xaa Xaa Phe Xaa Trp
1 5 10